Table 1.
Patients’ and tumors’ characteristics
| Characteristics |
Long‐term survivors (n = 39) N (%) |
Control group (n = 397) N (%) |
P value |
|---|---|---|---|
| Patients’ characteristics | |||
| Gender | |||
| Male | 13 (33.3) | 210 (52.9) | |
| Female | 26 (66.7) | 187 (47.1) | 0.020 |
| Age at metastasis stage | |||
| Median in years [range] | 46 [21‐77] | 59 [18‐92] | <0.001 |
| PS at metastasis stage | |||
| 0 | 26 (66.7) | 86 (43) | |
| 1 | 12 (30.8) | 81 (40.5) | |
| ≥2 | 1 (2.6) | 33 (16.5) | |
| Missing | 0 | 197 | 0.008 |
| Tumors’ characteristics | |||
| Tumor localization | |||
| Extremity | 16 (41) | 144 (36.3) | |
| Viscera/Retroperitoneum | 18 (46.2) | 153 (38.5) | |
| Trunk | 5 (12.8) | 46 (11.6) | |
| Other | 0 (0) | 54(13.6) | 0.045 |
| Histology | |||
| Leiomyosarcoma | 8 (20.5) | 21.4) | |
| Synovial sarcoma | 6 (15.4) | 32 (8.1) | |
| UPS | 5 (12.8) | 100 (25.2) | |
| Endometrial stromal sarcoma | 5 (12.8) | 1 (0.3) | |
| Liposarcoma | 3 (7.7) | 51 (12.8) | |
| Othersa | 12 (30.8) | 128 (32.2) | <0.001 |
| Size of tumor | |||
| ≤5 cm | 13 (36.1) | 68 (19.3) | |
| >5 cm | 23 (63.9) | 284 (80.7) | |
| Missing | 3 | 45 | 0.018 |
| Grade of tumor | |||
| G1 | 13 (33.3) | 18 (4.9) | |
| G2 | 13 (33.3) | 130 (35.1) | |
| G3 | 13 (33.3) | 222 (60) | |
| Missing | 0 | 27 | <0.001 |
| Tumor depthb | |||
| Deep | 36 (92) | 345 (86.9) | |
| Superficial | 3 (8) | 32 (8.1) | |
| Superficial and deep | 0 (0) | 20 (5) | 0.463 |
| Multifocal tumor | |||
| Yes | 6 (15) | 23 (22.5) | |
| No | 33(85) | 79 (77.5) | |
| Missing | 0 | 295 | 0.346 |
| Sarcoma genomics | |||
| Simple genomic sarcoma | 21 (53.8) | 134 (33.8) | |
| Complex genomic sarcoma | 18 (46.2) | 263 (66.2) | 0.012 |
| Simple genetic alteration | |||
| Translocation | 19 (90.5) | 88 (65.7) | |
| Amplification | 1 (4.8) | 42 (31.3) | |
| Activating mutation | 1 (4.8) | 1 (0.7) | |
| Inactivating mutation | 0 (0) | 3 (2.2) | 0.017 |
| Stage of disease | |||
| Metastatic disease at diagnosis | 14 (35.9) | 112 (8.2) | |
| Metastatic relapse | 25 (64.1) | 285 (71.8) | 0.312 |
| DFI (mo) | |||
| ≤24 | 25 (64) | 325 (82) | |
| >24 | 14 (36) | 72 (18) | 0.008 |
| Number of metastatic sites | |||
| 1 | 31 (79.5) | 257 (76.5) | |
| ≥2 | 8 (20.5) | 79 (23.5) | |
| Missing | 0 | 61 | 0.674 |
| Liver metastasis | 3 (7.7) | 88 (22.2) | |
| No liver metastasis | 3 (92.3) | 309 (77.8) | 0.034 |
DFI, disease‐free interval; PS, Performance status; UPS, Undifferentiated pleomorphic sarcoma.
Others: Angiosarcoma, Alveolar soft part sarcoma, Atypical lipomatous tumor, Clear cell sarcoma, Chondrosarcoma, Dermatofibrosarcoma protuberans, Desmoplastic round cell tumor, Ewing sarcoma, Epithelioid haemangioendothelioma, Epithelioid sarcoma, Fibromyxoid sarcoma, Inflammatory myofibroblastic tumor, Intimal sarcoma, Malignant hemangiopericytoma, Malignant solitary fibrous tumor, Malignant Peripheral Nerve Sheath Tumor, Myoepithelioma, Myxofibrosarcoma, Osteosarcoma, Rhabdomyosarcoma, Sclerosing epithelioid fibrosarcoma, PECOMA, Rhabdoid tumor, Rhabdomyosarcoma.
Superficial tumor is located exclusively above the superficial fascia without invasion of the fascia; deep tumor is located either exclusively beneath the superficial fascia, superficial to the fascia with invasion of the fascia, or both superficial yet beneath the fascia.